In the third quarter of 2022, market growth was constrained, according to Apixaban Pricing patterns. Due to a decrease in the supply of the API among manufacturers, Apixaban prices increased significantly in the North American market during the first half of Q3. The weak Apixaban market has been sustained by the meager downstream pharmaceutical demand. The US Federal Reserve's tight monetary policy and high-interest rates implemented around the end of the third quarter severely harmed the prospects for domestic commerce. Fears of a recession among traders have made the economic growth barriers stronger. The price of feedstock titanium dioxide among the dealers has also been negatively impacted by the declining price of crude oil. In the final phase of Q3 2022, the value accessed at USD 3250890/MT with an average quarterly declination of 1.43%.